<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03331406</url>
  </required_header>
  <id_info>
    <org_study_id>17-350</org_study_id>
    <nct_id>NCT03331406</nct_id>
  </id_info>
  <brief_title>Physical Activity In Gastrointestinal Cancer</brief_title>
  <official_title>A Pilot Study of Physical Activity in Older Adults With Metastatic Gastrointestinal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dana-Farber Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dana-Farber Cancer Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is evaluating the ability for people with metastatic gastrointestinal&#xD;
      cancer to participate in a physical activity program.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The physical activity program is 12-weeks in length, and includes moderate-intensity aerobic,&#xD;
      strength, flexibility, and balance training.&#xD;
&#xD;
        -  The goal of the aerobic training is to complete 150 minutes per week of brisk walking.&#xD;
&#xD;
        -  The goals of the strength, flexibility, and balance training are to engage in these&#xD;
           activities twice per week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2017</start_date>
  <completion_date type="Actual">January 22, 2019</completion_date>
  <primary_completion_date type="Actual">January 22, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Accrual</measure>
    <time_frame>12 months</time_frame>
    <description>Recruit 20 patients within 12 months</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants that adhered to physical activity program</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Demonstrate that at least 50% of patients adhered to at least 50% of the prescribed physical activity program.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of Retention</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Proportion of participants who complete the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants that complete assessment procedures</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Physical function testing and questionnaire collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>12 Weeks</time_frame>
    <description>Falls, hospitalizations, and musculoskeletal injury</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Metastatic Gastrointestinal Cancer</condition>
  <condition>Physical Activity</condition>
  <arm_group>
    <arm_group_label>12-week physical activity program</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The physical activity program is of moderate intensity and consists of aerobic, strength, flexibility, and balance training with a target duration of 150 minutes per week.&#xD;
At study start, participants will be provided with a pedometer to objectively monitor their aerobic activity, variable weight ankle weights and a medical journal to record physical activity.&#xD;
Exercise Trainer --A exercise trainer will be assigned to design a physical activity program.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical Activity Program</intervention_name>
    <description>12-weeks in length, and includes moderate-intensity aerobic, strength, flexibility, and balance training.</description>
    <arm_group_label>12-week physical activity program</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Start of trial:&#xD;
&#xD;
               -  A three-month of strict inclusion criteria (Phase 1).&#xD;
&#xD;
               -  At the end of three-months, if at least six participants have not been accrued,&#xD;
                  inclusion criteria will be expanded for a second three-month recruitment phase&#xD;
                  (Phase 2).&#xD;
&#xD;
               -  At the end of six-months, an average of two patients per month has not been&#xD;
                  accrued, a further expand inclusion criteria (Phase 3).&#xD;
&#xD;
          -  Phase 1 (most strict) Eligibility criteria include:&#xD;
&#xD;
               -  Voluntary, signed informed consent;&#xD;
&#xD;
               -  Diagnosis of histologically-confirmed esophageal, gastric, pancreatic, or&#xD;
                  colorectal that is metastatic or locally-advanced (unresectable);&#xD;
&#xD;
               -  First-line cytotoxic chemotherapy started within four-weeks of enrollment&#xD;
                  (patients can have reviewed prior adjuvant therapy if completed ≥6 months prior&#xD;
                  to start of first line chemotherapy for metastatic disease);&#xD;
&#xD;
               -  Age greater than 65 years;&#xD;
&#xD;
               -  Baseline weight-bearing physical activity less than 150 min∙wk-1 using the&#xD;
                  Paffenbarger physical activity questionnaire;&#xD;
&#xD;
               -  Eastern Cooperative Group Performance Status of 0, 1, or 2;&#xD;
&#xD;
               -  Self-reported ability to walk 400-meters (approximately one city block) without&#xD;
                  sitting, leaning, or the help of another person or walker;&#xD;
&#xD;
               -  Written physician approval;&#xD;
&#xD;
               -  Life expectancy &gt;3 months;&#xD;
&#xD;
               -  English speaking.&#xD;
&#xD;
          -  Phase 2 (less restrictive) Eligibility criteria will loosen:&#xD;
&#xD;
             -- The minimum age from greater than 65, to greater than 55;&#xD;
&#xD;
          -  Phase 3 (least restrictive) Eligibility criteria will add:&#xD;
&#xD;
             -- The minimum age from greater than 55, to greater than 18.&#xD;
&#xD;
          -  Exclusion Criteria&#xD;
&#xD;
               -  Known or suspected brain or other central nervous system metastases;&#xD;
&#xD;
               -  Uncontrolled cardiac or pulmonary disease;&#xD;
&#xD;
               -  Pregnant or breast feeding;&#xD;
&#xD;
               -  Any other condition that may impede testing of the study hypothesis, make it&#xD;
                  unsafe to engage in the physical activity program, or make the participant not&#xD;
                  available for end of study assessments (determined by the investigative team).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Meyerhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dana-Farber Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>November 1, 2017</study_first_submitted>
  <study_first_submitted_qc>November 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 6, 2017</study_first_posted>
  <last_update_submitted>March 10, 2020</last_update_submitted>
  <last_update_submitted_qc>March 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dana-Farber Cancer Institute</investigator_affiliation>
    <investigator_full_name>Jeffrey A. Meyerhardt, MD</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>Metastatic gastrointestinal cancer</keyword>
  <keyword>Physical Activity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

